Equities

Akebia Therapeutics Inc

Akebia Therapeutics Inc

Actions
  • Price (EUR)1.18
  • Today's Change0.01 / 0.86%
  • Shares traded15.00k
  • 1 Year change+4.63%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Akebia Therapeutics Inc has grown net income from a loss of -94.23m to a smaller loss of -51.93m despite falling revenues.
Gross margin82.59%
Net profit margin-23.18%
Operating margin-20.54%
Return on assets-17.07%
Return on equity--
Return on investment-29.47%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Akebia Therapeutics Inc fell by 48.59m. However, Cash Flow from Investing was flat, indicating that little new money was committed to growth. In addition the company used 23.38m for operations while cash used for financing totalled 25.21m.
Cash flow per share-0.0144
Price/Cash flow per share--
Book value per share-0.1608
Tangible book value per share-0.5279
More ▼

Balance sheet in USDView more

Akebia Therapeutics Inc has a Debt to Total Capital ratio of 889.20%.
Current ratio1.04
Quick ratio0.8222
Total debt/total equity--
Total debt/total capital8.89
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.